Humira
RA setbacks for AstraZeneca and Lilly
December 14, 2012Research and Development, Sales and Marketing AstraZeneca, Humira, RA, lilly
AstraZeneca and Eli Lilly have both suffered setbacks in their attempts to push their respective investigational rheumatoid arthritis (RA) treatments …
Another indication for Humira
November 28, 2012Sales and Marketing Abbott, Crohn's, EU, Humira
Abbott’s Humira has received its ninth indication in Europe with approval to treat youngsters suffering from the inflammatory bowel disease …
Humira continues to drive Abbott
October 22, 2012Sales and Marketing AbVie, Abbott, Humira, RA
Abbott Laboratories’ rheumatoid arthritis drug Humira has once again shown its value to the company with a strong performance in …
Humira powers ahead as Abbott prepares split
July 19, 2012Sales and Marketing AbbVie, Abbott, Humira, RA
Humira maintained its rapid growth in the second quarter, helping keep Abbott buoyant ahead of its split into two separate …
AstraZeneca buys Ardea Biosciences
June 22, 2012Research and Development, Sales and Marketing Abbott, Ardea Biosciences, AstraZeneca, Bayer, Humira, Takeda
AstraZeneca has completed its acquisition of US firm Ardea Biosciences in a $1.26 billion deal that it hopes will shore …
RoActemra superior to Humira as single-agent therapy
June 7, 2012Research and Development, Sales and Marketing Humira, Orencia, RA, RoActemra, Roche. ADACTA
Roche’s RoActemra (tocilizumab) is more effective in treating rheumatoid arthritis as a single agent than market leader Humira, a new …
Pfizer’s RA drug on course for approval
May 10, 2012Sales and Marketing Humira, JAK inhibitor, Pfizer, RA, rheumatoid arthritis, tofacitinib
An FDA advisory committee has recommended for approval Pfizer’s new rheumatoid arthritis treatment tofacitinib.The Arthritis Advisory Committee voted 8-2 to …
Humira gains European licence for ulcerative colitis
April 11, 2012Sales and Marketing Humira, ulcerative colitis
Abbott’s Humira has gained European approval to treat ulcerative colitis, adding to its six existing licences. It can now …
Roche’s RoActemra beats Humira in arthritis study
March 5, 2012Research and Development, Sales and Marketing Humira, RA, RoActemra, Roche, arthritis
Roche’s rheumatoid arthritis drug RoActemra has beaten Abbott’s Humira in a head-to-head study. The Phase IV trial showed that RoActemra …
Abbott buys into Galapagos’ RA candidate
February 29, 2012Research and Development, Sales and Marketing Abbott, Galapagos, Humira, JAK, RA, TNF
Abbott has struck a deal with Galapagos to develop and commercialise a promising oral JAK1 inhibitor to treat multiple autoimmune …
Abbott strong as it prepares for spin-out
January 26, 2012Sales and Marketing Abbott, GAAP, Humira
Abbott enjoyed a strong 2011 thanks to Humira and emerging market growth, with overall worldwide sales rising by 4.1 per …
Abbott spin-off could attract mega merger
October 21, 2011Research and Development, Sales and Marketing Abbott, Bayer, Humira, Merck, Roche
Abbott’s new spin-off pharma firm could attract a lot of attention from big pharma looking to sure up their portfolios. …
NICE re-thinks arthritis guidance
June 25, 2010Sales and Marketing Enbrel, Humira, MabThera, NICE, Orencia, Remicade, TNF, rheumatoid arthritis
NICE has approved five rheumatoid arthritis treatments in certain circumstances after treatment with a tumour necrosis factor inhibitor has failed. …
Pfizer still at number 1, but Lipitor to slip
May 4, 2010Sales and Marketing Humira, Lipitor, Pfizer, sales
New research suggests that the pharma world is going to be shaken up over the next few years – although …
Ulcerative colitis market set to double by 2018
February 12, 2010Sales and Marketing Humira, Simponi, TNF, ulcerative colitis
The market for ulcerative colitis drugs is set to double over the ten years to 2018 when it will hit …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
